Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine
Poliomyelitis
About this trial
This is an interventional prevention trial for Poliomyelitis focused on measuring bOPV, IPV, Sequential immunization, Immunity Duration, Booster Immunization
Eligibility Criteria
Inclusion Criteria:
- Subjects who have already taken part in phase 3 clinical trail in Guangxi and were vaccinated 3-dose primary immunization with polio vaccines .Moreover,the results of the selected paired serum are required.
- 24 months old(calendar month).
- Guardians understand the contents and requirements of this trail , meanwhile, voluntarily joined this study with informed consents.
- Able to attend all scheduled visits and to comply with all trial procedures(including vaccinate and blood collection)
Exclusion Criteria:
- Any booster immunization with polio vaccine after finishing 3-dose primary immunizations research.
- Polio virus infection was demonstrated in laboratory experiment.
- Participation in another clinical trial at the same times.
- Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives or increase the risk of subjects,such as acute or chronic diseases 、some abnormal detected by lab,and so on.
Sites / Locations
- Guangxi Provincial Center for Diseases Control and PreventionRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
bOPV(Candy)
bOPV(Liquid)
bOPV(liquid)
bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50,type 3 polio virus ≥5.3lgCCID50.
bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml,type1 polio virus≥7.0 lgCCID50/ml,type 3 polio virus ≥6.5lgCCID50/ml.(2 drops each person;be be equivalent to 0.1ml each person )
bOPV(Liquid):Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral Produced by Beijing Tiantan Biological Products Co., Ltd. 1.0ml each bottle,2 drops each person(be be equivalent to 0.1ml each person).(total content of polio virus≥6.12lgCCID50,type1 polio virus≥6.0 lgCCID50,type 3 polio virus ≥5.5lgCCID50 in each 0.1 ml)